Drug Metab Dispos 2020 10 14;48(10):873-885. Epub 2020 Jul 14.
PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., G.R., U.P., H.B., A.M., G.C., S.Z.); Preclinical Safety, Novartis Pharma AG, Basel, Switzerland (R.H.); Novartis Global Discovery Chemistry, Novartis Pharma AG, Basel, Switzerland (K.S., A.M.); and PRA Health Sciences, The Netherlands (J.J.v.L.).
Capmatinib (INC280), a highly selective and potent inhibitor of the MET receptor tyrosine kinase, has demonstrated clinically meaningful efficacy and a manageable safety profile in patients with advanced non-small-cell lung cancer harboring exon 14-skipping mutations. We investigated the absorption, distribution, metabolism, and excretion of capmatinib in six healthy male volunteers after a single peroral dose of 600 mg C-labeled capmatinib. The mass balance, blood and plasma radioactivity, and plasma capmatinib concentrations were determined along with metabolite profiles in plasma, urine, and feces. Read More